The impact of direct antiviral agents on the development and recurrence of hepatocellular carcinoma

Liver International

Volumn 37, Issue , 2017, Pages 136-139

  Reig, María ^a   Boix, Loreto ^a   Bruix, Jordi ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

DAAs; hepatocellular carcinoma; incidence; recurrence

Indexed keywords

ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; CANCER RECURRENCE; CLINICAL TRIAL (TOPIC); HUMAN; LIVER CELL CARCINOMA; RECURRENT DISEASE; REVIEW; STUDY DESIGN; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; COMPLICATION; GENETICS; HEPACIVIRUS; HEPATITIS B VIRUS; HERPES SIMPLEX; INCIDENCE; LIVER TUMOR; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIMPLEXVIRUS; TUMOR RECURRENCE; VIROLOGY; VIRUS ACTIVATION;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPACIVIRUS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HERPES SIMPLEX; HUMANS; INCIDENCE; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIMPLEXVIRUS; VIRUS ACTIVATION;

EID: 85007583439     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13321     Document Type: Review

References (14)

1. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2016; doi: 10.1016/j.jhep.2016.09.001 [cited 2016 Nov 8].
2. Collins JM, Raphael KL, Terry C, et al. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis 2015;61:1304–1306.
3. EMA reviews direct-acting antivirals for hepatitis C. EMA Rev. direct-acting antivirals Hepat. C. 2016; http://www.ema.europa.eu/docs/en_GB/document_libra. Accessed 07_October_2016.
4. Welker M-W, Luhne S, Lange CM, et al. Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment. J Hepatol 2016;64:790–799.
5. Perelló CS, Fernández-Carrillo C, Londoño M-C, et al. Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol. 2016; 14:1662–1666.e1
6. Reig M, Mariño Z, Perelló C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016;65:719–726.
7. Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65:727–733.
8. Kozbial K, Moser S, Schwarzer R, et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. J Hepatol 2016;65:856–858.
9. Yang JD, Aqel BA, Pungpapong S, Gores GJ, Roberts LR, Leise MD. Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. J Hepatol 2016;65:859–860.
10. ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Electronic address: stanislas.pol @aphp.fr. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol. 2016;65:734–740.
11. Torres HA, Vauthey J-N, Economides MP, Mahale P, Kaseb A. Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: first, do no harm by withdrawing treatment. J Hepatol 2016;65:862–864.
12. Ganne-Carrié N, Layese R, Bourcier V, et al. Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir). Hepatology 2016;64:1136–47.
13. Therapeutic Option for Hepatitis B and C: a French Cohort.Carrat F, on behalf of ANRS/AFEF. Clinical outcomes in hcv-infected patients treated with direct acting antivirals – 18 month post-treatment follow-up in the french anrs co22 hepather cohort study. J Hepatol 2016;64:S215.
14. Trinchet J-C, Bourcier V, Chaffaut C, et al. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort). Hepatology 2015;62:737–750.